Drugs / IMM60
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05709821 | Nov 2023 → Apr 2024 | melanoma, non-small cell lung carcinoma | iOx Therapeutics | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM60 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05709821 ↗ |